Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new ...

Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who ...

Amgen (AMGN) announced that the global Phase 3 DeLLphi-304 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Amgen (NASDAQ:AMGN), a biotechnology leader with a market capitalization of $151.3 billion and impressive gross margins of nearly 69%, reported that its Phase 3 DeLLphi-304 clinical trial, evaluating ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Amgen’s AMGN stock has risen 21.7% so far ... An interesting BiTE drug, Imdelltra (tarlatamab), was approved for pre-treated ...

Withhold or permanently discontinue IMDELLTRA ® based on severity. This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen.

April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...